Skip to main content
    P

    PolyPid (PYPD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.15
    -0.11 (-1.76%)

    Market Cap: $132.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PolyPid (PYPD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect PolyPid (PYPD) to earn $0.10 per share in the fiscal year ending Dec 31, 2026, on revenue of $21.05M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates fall 54.1%.

    Fiscal year ending Dec 31, 2026
    $0.10
    EPS consensus, revenue $21.05M
    Fiscal year ending Dec 31, 2027
    -$0.96
    EPS consensus, revenue $9.67M
    Next report
    Feb 9, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.10-$0.17 to $0.523$21.05MN/A5
    Dec 31, 2027-$0.96-$1.82 to -$0.325$9.67M$2.80M to $13.64M5

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.41-$0.55 to -$0.307

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202722

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a loss of $0.89 to a profit.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.10-$0.61-$0.89-$0.89-$0.89N/A
    Fiscal year ending Dec 31, 2027-$0.96-$1.05-$1.23-$1.23-$1.23N/A

    Frequently Asked Questions About PYPD

    What is the PYPD stock forecast?

    Consensus analyst estimates put PolyPid's EPS at $0.10 for the fiscal year ending Dec 31, 2026, on revenue of $21.05M. The consensus rating from 5 analysts is Buy.

    How do analysts rate PYPD stock?

    Of 5 analysts covering PolyPid, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PYPD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.10, with estimates from -$0.17 to $0.52 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.96, with estimates from -$1.82 to -$0.32 from 5 analysts.

    What revenue do analysts expect from PolyPid next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $21.05M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $9.67M, with estimates from $2.80M to $13.64M.

    How many analysts cover PYPD?

    5 analysts rate PolyPid stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.